# Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring

Study · id `cardio:ct-nct03426982` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03426982](<https://clinicaltrials.gov/study/NCT03426982>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03426982

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 700 participants.

## Technical summary

Registry record NCT03426982. Randomized; no masking; primary purpose supportive care. Start 2018-03-01 (actual); primary completion 2018-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT03426982, source copy `cardio:ctgov-nct03426982-2018-03-14`, retrieved 2026-10-26)
- Started: 2018-03-01 (actual) (ClinicalTrials.gov record NCT03426982, source copy `cardio:ctgov-nct03426982-2018-03-14`, retrieved 2026-10-26)
- Primary completion: 2018-10-01 (anticipated) (ClinicalTrials.gov record NCT03426982, source copy `cardio:ctgov-nct03426982-2018-03-14`, retrieved 2026-10-26)
- Completion: 2018-10-30 (anticipated) (ClinicalTrials.gov record NCT03426982, source copy `cardio:ctgov-nct03426982-2018-03-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03426982, source copy `cardio:ctgov-nct03426982-2018-03-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03426982-2018-03-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring
- Acronym: CATCH
- Condition: Myocardial Infarction
- Condition: Venous Thromboembolism
- Condition: Stroke
- Condition: Bleeding
- Intervention (Drug): Unfractionated heparin
- Intervention (Drug): Unfractionated heparin
- Lead sponsor: Wuhan Asia Heart Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: Wuhan Asia Heart Hospital (`cardio:org-wuhan-asia-heart-hospital`)

## Provenance

Content hash: c8dc95453b5a73dbbcde96c2f236b8b93f760233cac418e405e9cb3681c4299b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
